Table 2.
Comparison of hemodynamic characteristics between the high blood pressure (HighBP) group and the cardiac failure (CF) group. IVSd: Interventricular septum diameter.
| HighBP | CF | p | |||
|---|---|---|---|---|---|
| n = 12 | n = 15 | ||||
| Birth | |||||
| Gestational age, median (Q1–Q3) | 29 | (28–30) | 29 | (28–31) | 0.77 |
| Weight (g), median (Q1–Q3) | 1293 | (1168–1533) | 1265 | (1150–1607) | 0.98 |
| Weight (percentile), median (Q1–Q3) | 71 | (55–79) | 66 | (34–75) | 0.26 |
| % difference of weight with the twin, median (Q1–Q3) | 22.8 | (11.8–30.1) | 18.2 | (12.9–22.8) | 0.51 |
| APGAR score | |||||
| 1 min, median (Q1–Q3) | 6 | (4–8) | 5 | (2–6) | 0.35 |
| 5 min, median (Q1–Q3) | 9 | (8,9) | 8 | (4–9) | 0.15 |
| Umbilical cord pH, median (Q1–Q3) | 7.37 | (7.36–7.39) | 7.30 | (7.26–7.37) | 0.05 |
| Hemodynamic characteristics | |||||
| High systolic blood pressure, n (%) | 12 | (100) | 15 | (100) | 1.00 |
| Ventricular hypertrophy, n (%) | 12 | (100) | 15 | (100) | 1.00 |
| Maximum IVSd (mm), median (Q1–Q3) | 4.2 | (3.8–5.1) | 5.0 | (4.2–5.3) | 0.32 |
| Hydrocortisone hemisuccinate, n (%) | 2 | (17) | 6 | (40) | 0.41 |
| Renal-dose dopamine, n (%) | 0 | (0) | 4 | (27) | 0.10 |
| Fluid expension with saline solution, n (%) | 1 | (8) | 8 | (53) | 0.019 |
| Antihypertensive treatment | |||||
| Nicardipine, n (%) | 12 | (100) | 15 | (100) | 1.00 |
| Starting time (hours of life), median (Q1–Q3) | 4 | (4–23) | 3 | (2–16) | 0.18 |
| Maximal dose (μg/kg/min), median (Q1–Q3) | 0.6 | (0.5–1.2) | 1.0 | (0.7–1.8) | 0.08 |
| Inotropic treatment (Milrinone, Dobutamine), n (%) | 0 | (0) | 14 | (93) | |
| Milrinone, n (%) | 5 | (33) | |||
| Starting time (hours of life), median (Q1–Q3) | 22 | (16–39) | |||
| Maximal dose (μg/kg/min), median (Q1–Q3) | 0.2 | (0.2–0.2) | |||
| Dobutamine, n (%) | 13 | (87) | |||
| Starting time (hours of life), median (Q1–Q3) | 13 | (6–26) | |||
| Maximal dose (μg/kg/min), median (Q1–Q3) | 20.0 | (15.0–20.0) | |||
| Biological parameters | |||||
| pH in the first 2 days of life, median (Q1–Q3) | 7.33 | (7.29–7.37) | 7.26 | (7.23–7.29) | <0.001 |
| Lactate in the first 2 days of life, median (Q1–Q3) | 1.6 | (1.2–2.2) | 2.1 | (1.5–3.3) | 0.07 |
| Acute kidney injury, n (%) | 3 | (25) | 14 | (93) | <0.001 |
| Stage 1 of KDIGO classification, n (%) | 2 | (17) | 1 | (7) | 0.57 |
| Stage 2 of KDIGO classification, n (%) | 1 | (8) | 0 | (0) | 0.44 |
| Stage 3 of KDIGO classification, n (%) | 0 | (0) | 13 | (87) | <0.001 |
| Maximum serum blood urea nitrogen (mmol/L), median (Q1–Q3) | 6.7 | (6.1–8.0) | 13.3 | (8.8–17.9) | 0.003 |
| Maximum serum creatinine (µmol/L), median (Q1–Q3) | 77.0 | (62.3–87.5) | 134.0 | (90.8–157.8) | 0.005 |
| Urinary examinations, n (%) | 9 | (75) | 5 | (33) | |
| Urinary sodium excretion (mmol/L), median (Q1–Q3) | 38.0 | (33.0–54.0) | 28.5 | (13.0–36.0) | 0.011 |
| Proteinuria (g/L), median (Q1–Q3) | 0.15 | (0.08–0.24) | 0.30 | (0.18–0.49) | 0.032 |
| Urinary to serum ratio of urea nitrogen, median (Q1–Q3) | 8.34 | (7.08–8.70) | 5.74 | (3.28–6.51) | 0.017 |
| Urinary to serum ratio of creatinine, median (Q1–Q3) | 10.74 | (9.24–13.17) | 11.92 | (6.30–19.34) | 0.44 |
| Urinary sodium to potassium excretion ratio, median (Q1–Q3) | 5.17 | (3.26–8.65) | 1.44 | (0.99–1.62) | <0.001 |